Filed Pursuant to Rule 424(b)(5)
Registration No. 333-276399
PROSPECTUS SUPPLEMENT
(To prospectus dated January 5, 2024)
3,500,000 Shares

Common Stock
We are offering 3,500,000 shares of our common stock, par value $0.01 per share (“common stock”). We expect to enter into separate forward sale agreements with each of BofA Securities, Inc., J.P. Morgan Securities LLC and KeyBanc Capital Markets Inc. (or their respective affiliates), whom we refer to in such capacity as the forward purchasers. In connection with the forward sale agreements, the forward purchasers (or their respective affiliates) are expected to borrow from third parties and to sell to the underwriters an aggregate of 3,500,000 shares of our common stock that will be sold in this offering. We will not initially receive any proceeds from the sale of shares of our common stock by the forward purchasers (or their respective affiliates), except in certain circumstances described in this prospectus supplement. We expect to physically settle the forward sale agreements and receive proceeds, subject to certain adjustments, from the sale of those shares of our common stock upon one or more such physical settlements within approximately one year from the date of this prospectus supplement. Although we expect to settle the forward sale agreements entirely by the physical delivery of shares of our common stock in exchange for cash proceeds, we may elect cash settlement or net share settlement for all or a portion of our obligations under the forward sale agreements, in which case, we may receive, or we may owe, cash or shares of our common stock from or to the forward purchasers. See “Underwriting— Forward Sale Agreements” in this prospectus supplement.
If the forward purchasers (or their respective affiliates) do not deliver and sell all of the shares of our common stock to be sold by them to the underwriters, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that the forward purchasers (or their respective affiliates) do not deliver and sell, and the number of shares underlying the forward sale agreements will be decreased by the number of shares that we issue and sell.
Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “GTY.” The last reported sale price of our common stock on the NYSE on July 29, 2024 was $31.51 per share.
In order to preserve our status as a real estate investment trust (“REIT”) for federal income tax purposes, among other purposes, our charter imposes certain restrictions on ownership of our common stock. See “Description of Capital Stock—Ownership and Transfer Restrictions” in the accompanying prospectus.
Investing in our common stock involves risks. See the information under the captions “Risk Factors” beginning on page S-6 of this prospectus supplement and beginning on page 3 of the accompanying prospectus, as well as the information under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, which is incorporated by reference in this prospectus supplement.
| | | | | | | | |
| | Per Share | | | Total(1) | |
Public offering price | | $ | 30.100 | | | $ | 105,350,000 | |
Underwriting discounts and commissions(2) | | $ | 1.204 | | | $ | 4,214,000 | |
Proceeds, before expenses, to us(3) | | $ | 28.896 | | | $ | 101,136,000 | |
(1) | Assumes no exercise of the underwriters’ option to purchase additional shares described below. |
(2) | See “Underwriting” for a description of all compensation payable to the underwriters. |
(3) | We have assumed that the forward sale agreements will be fully physically settled based on a forward sale price equal to the initial forward sale price of $28.896 per share, which is the public offering price less the underwriting discounts and commissions shown above. The forward sale price is subject to adjustment pursuant to the terms of each forward sale agreement, and the actual proceeds, if any, to us will be calculated as described in this prospectus supplement. “Underwriting—Forward Sale Agreements” for a description of the forward sale agreements. |
The underwriters have been granted a 30-day option from the date of this prospectus supplement, exercisable in whole or in part from time to time, to purchase up to an additional 525,000 shares of our common stock at the public offering price per share set forth on the cover page of this prospectus supplement, less the underwriting discounts and commissions and any dividends or distributions payable on the shares initially purchased by the underwriters but not payable on such option shares. Upon any exercise of such option, we expect to enter into additional forward sale agreements with the forward purchasers in respect of the number of shares sold by the forward purchasers (or their respective affiliates) in connection with the exercise of such option. Unless the context requires otherwise, the term “forward sale agreements,” as used in this prospectus supplement, includes any additional forward sale agreements that we enter into in connection with the exercise by the underwriters of their option to purchase additional shares. In such event, if the forward purchasers (or their respective affiliates) do not deliver and sell all of the shares of our common stock to be sold by them to the underwriters in connection with the exercise of such option, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that the forward purchasers (or their respective affiliates) do not deliver and sell, and the number of shares underlying the additional forward sale agreements will be decreased by the number of shares that we issue and sell.
Neither the SEC nor any state or other securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The shares of common stock will be ready for delivery on or about July 31, 2024.
Joint Book-Running Managers
| | | | |
BofA Securities | | J.P. Morgan | | KeyBanc Capital Markets |
Book-Running Managers
| | |
Goldman Sachs & Co. LLC | | TD Securities |
Co-Managers
| | | | | | |
Baird | | Capital One Securities | | Citizens JMP | | BTIG |
The date of this prospectus supplement is July 29, 2024.